Hint mode is switched on Switch off
For swift navigation between sections

Organization: Ligand
LEI 5493008K7TB0IKP37H79

Organization name
Ligand Pharmaceuticals, Inc
Country name
USA
Country of registration
USA
Industry
Pharmaceutical Preparation and Biotechnology
Bond debt
148 mln USD

Find Any Data on Any Bond in Just One Click

Full data on over 500,000 bonds and stocks worldwide

Powerful bond screener

Ratings from the top 3 global ratings agencies, plus over 70 local ones

Over 300 pricing sources from the OTC market and world stock exchanges

User-friendly and intuitive across multiple platforms

Get access

Latest data on

Profile

Ligand Pharmaceuticals Incorporated (Ligand) is a biotechnology company that operates with a business model focused on developing or acquiring assets. The Company’s technology portfolio CAPTISOL is a formulation technology that has enabled five Food and Drug Administration (FDA) approved products, including Pfizer’s VFEND IV and Baxter International’s Nexterone and is being used in a number of clinical-stage partner programs. The therapies in its portfolio in development address the unmet medical needs of patients for a spectrum of diseases, including hepatitis, muscle wasting, Alzheimer’s disease, dyslipidemia, diabetes, anemia, asthma, rheumatoid arthritis and osteoporosis. It’s wholly owned subsidiaries include Ligand JVR, Allergan Ligand Retinoid Therapeutics, Seragen, Inc., Pharmacopeia, LLC, Neurogen Corporation, CyDex Pharmaceuticals, Inc. and Metabasis Therapeutics. 

Awards

Documentation

Stocks

Latest issues

Bond debt by currency

Codes

  • LEI
    5493008K7TB0IKP37H79
  • SIC
    2834 PHARMACEUTICAL PREPARATIONS
  • CIK
    0000886163

Credit ratings

Macroeconomic Indicators - Ligand

Registration is required to get access.